Association of Multitrajectories of Lipid Indices With Premature Cardiovascular Disease: A Cohort Study

Background The multitrajectory model can identify joint longitudinal patterns of different lipids simultaneously, which might help better understand the heterogeneous risk of premature cardiovascular disease (CVD) and facilitate targeted prevention programs. This study aimed to investigate the associations between multitrajectories of lipids with premature CVD. Methods and Results The study enrolled 78 526 participants from the Kailuan study, a prospective cohort study in Tangshan, China. Five distinct multitrajectories of triglyceride, low‐density lipoprotein cholesterol (LDL‐C), and high‐density lipoprotein cholesterol over 6‐year exposure were identified on the basis of Nagin's criteria, using group‐based multitrajectory modeling. During a median follow‐up of 6.75 years (507 645.94 person‐years), 665 (0.85%) premature CVDs occurred. After adjustment for confounders, the highest risk of premature CVD was observed in group 4 (the highest and increasing triglyceride, optimal and decreasing LDL‐C, low and decreasing high‐density lipoprotein cholesterol) (hazard ratio [HR], 2.13 [95% CI, 1.36–3.32]), followed by group 5 (high and decreasing triglyceride, optimal and increasing LDL‐C, low and decreasing high‐density lipoprotein cholesterol) (HR, 2.07 [95% CI, 1.45–2.98]), and group 3 (optimal and increasing triglyceride, borderline high and increasing LDL‐C, optimal and decreasing high‐density lipoprotein cholesterol) (HR, 1.90 [95% CI, 1.32–2.73]). Conclusions Our results showed that the residual risk of premature CVD caused by increasing triglyceride levels remained high despite the fact that LDL‐C levels were optimal or declining over time. These findings emphasized the importance of assessing the joint longitudinal patterns of lipids and undertaking potential interventions on triglyceride lowering to reduce the residual risk of premature CVD, even among individuals with optimal LDL‐C levels.

[1]  Shuohua Chen,et al.  U-Shaped Relationship of High-Density Lipoprotein Cholesterol and Incidence of Total, Ischemic and Hemorrhagic Stroke: A Prospective Cohort Study , 2022, Stroke.

[2]  M. Pletcher,et al.  Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events. , 2021, JAMA cardiology.

[3]  M. Mansournia,et al.  Multi-trajectories of lipid indices with incident cardiovascular disease, heart failure, and all-cause mortality: 23 years follow-up of two US cohort studies , 2021, Journal of translational medicine.

[4]  Hao Li,et al.  Cumulative burden of lipid profiles predict future incidence of ischaemic stroke and residual risk , 2021, Stroke and vascular neurology.

[5]  D. Corella,et al.  Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease. , 2020, Journal of the American College of Cardiology.

[6]  H. Iso,et al.  Reader response: Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: A prospective study , 2020, Neurology.

[7]  Shuohua Chen,et al.  Association of Age of Onset of Hypertension With Cardiovascular Diseases and Mortality. , 2020, Journal of the American College of Cardiology.

[8]  Neha J. Pagidipati,et al.  The association between triglycerides and incident cardiovascular disease: What is "optimal"? , 2020, Journal of clinical lipidology.

[9]  Shuohua Chen,et al.  Association of changes in lipids with risk of myocardial infarction among people without lipid-lowering therapy. , 2020, Atherosclerosis.

[10]  Yongjun Wang,et al.  Visit-to-Visit Variability of Lipids Measurements and the Risk of Stroke and Stroke Types: A Prospective Cohort Study , 2020, Journal of stroke.

[11]  P. Austin,et al.  Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. , 2019, European heart journal.

[12]  F. Xue,et al.  Trajectories of Lipids Profile and Incident Cardiovascular Disease Risk: A Longitudinal Cohort Study , 2019, Journal of the American Heart Association.

[13]  R. Giugliano,et al.  Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. , 2019, Circulation.

[14]  M. Pencina,et al.  Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention. , 2019, Journal of the American College of Cardiology.

[15]  K. Kario,et al.  Target of Triglycerides as Residual Risk for Cardiovascular Events in Patients With Coronary Artery Disease - Post Hoc Analysis of the FMD-J Study A. , 2019, Circulation journal : official journal of the Japanese Circulation Society.

[16]  C. Bouchard,et al.  LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study. , 2019, Atherosclerosis.

[17]  Deepak L. Bhatt,et al.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.

[18]  K. Reynolds,et al.  Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol , 2018, Diabetes, obesity & metabolism.

[19]  Valéria Lima Passos,et al.  Group-based multi-trajectory modeling , 2018, Statistical methods in medical research.

[20]  Deepak L. Bhatt,et al.  Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. , 2018, Journal of the American College of Cardiology.

[21]  Seulggie Choi,et al.  Effect of Change in Total Cholesterol Levels on Cardiovascular Disease Among Young Adults , 2018, Journal of the American Heart Association.

[22]  P. Cook,et al.  Managing dyslipidaemia for the primary prevention of cardiovascular disease , 2018, British Medical Journal.

[23]  Jian‐Jun Li,et al.  2016 Chinese guidelines for the management of dyslipidemia in adults , 2018, Journal of geriatric cardiology : JGC.

[24]  F. Hu,et al.  Longitudinal Change in Fasting Blood Glucose and Myocardial Infarction Risk in a Population Without Diabetes , 2017, Diabetes Care.

[25]  T. Ivanova,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice , 2016 .

[26]  H. Nathoe,et al.  Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease. , 2016, The American journal of cardiology.

[27]  D. Demicco,et al.  Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. , 2015, Journal of the American College of Cardiology.

[28]  Marja-Riitta Taskinen,et al.  New insights into the pathophysiology of dyslipidemia in type 2 diabetes. , 2015, Atherosclerosis.

[29]  D. Nagin Group-Based Trajectory Modeling: An Overview , 2014, Annals of Nutrition and Metabolism.

[30]  Anette Varbo,et al.  Triglycerides and cardiovascular disease , 2014, The Lancet.

[31]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[32]  B. Nordestgaard,et al.  Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.

[33]  S. Yusuf,et al.  n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. , 2012, The New England journal of medicine.

[34]  Gyeong-Moon Kim,et al.  Association Between Changes in Lipid Profiles and Progression of Symptomatic Intracranial Atherosclerotic Stenosis: A Prospective Multicenter Study , 2012, Stroke.

[35]  Daniel S. Nagin,et al.  A Note on a Stata Plugin for Estimating Group-based Trajectory Models , 2012 .

[36]  Moshe Levi,et al.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[37]  M. Viitanen,et al.  Longitudinal changes in serum lipids in older people the Turku elderly study 1991-2006. , 2011, Age and ageing.

[38]  Daniel S Nagin,et al.  Group-based trajectory modeling in clinical research. , 2010, Annual review of clinical psychology.

[39]  G. Boysen,et al.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[40]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .

[41]  Shumei S. Sun,et al.  Lipids, lipoproteins, lifestyle, adiposity and fat-free mass during middle age: the Fels Longitudinal Study , 2006, International Journal of Obesity.

[42]  K. Roeder,et al.  A SAS Procedure Based on Mixture Models for Estimating Developmental Trajectories , 2001 .

[43]  H. Tunstall-Pedoe,et al.  Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents , 1994, Circulation.

[44]  Lippincott Williams Wilkins,et al.  Stroke--1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. , 1989, Stroke.

[45]  T. Golper,et al.  Lipid Lowering Agents 1 , 1989 .

[46]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[47]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .

[48]  D. Atar,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .